Promega, CS348803, Canine PD-1/PD-L1 Blockade Bioassay

Leading the Pack: Canine PD-1/PD-L1 Blockade Bioassay
Canine immune checkpoint therapeutics are a recent development in companion animal medicine, building on the success of immune-checkpoint inhibitor treatment in humans. Similar to their human counterpart, the canine immune system relies on checkpoint molecules on immune cells to control an immune response, but this mechanism has also been exploited by canine tumors to avoid detection. Emerging studies in veterinary oncology are focused on discovering and developing canine-targeted antibodies for immune checkpoints, such as CTLA-4 and PD-1/PD-L1.
There are several challenges to developing canine-specific antibodies for immune checkpoints, such as low-efficacy and low-throughput screening measures due to lack of standardized reagents and protocols, leading to labor-intensive assays with high levels of variability. The Canine PD-1/PD-L1 Blockade Bioassay is a two-cell-line system, a target cell that expresses canine PD-L1 and an effector reporter cell that expresses canine PD-1. The assay is a biologically relevant MoA-based and robust system that can be used to measure the potency and stability of biologics designed to block canine PD-1/PD-L1 interaction. This bioassay reduces data variability and provides a convenient luminescent readout.